Quick Read – McDonald’s 12% year-to-date slide pushes its yield to 3%, while AbbVie’s Skyrizi and Rinvoq replaced Humira and drove management to raise full-year guidance. – Lowe’s contrarian case rests on a housing lock-in effect trapping homeowners in place and redirecting…
ending toward renovation over relocation. – MCD faces margin pressure at a forward P/E of 21, ABBV carries negative shareholders’ equity, and LOW needs a housing recovery that hasn’t fully arrived. – Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and AbbVie didn’t make the cut. Grab the names FREE today
Dividend Aristocrats, the S&P 500 companies that have raised payouts for 25 or more consecutive years, remain the bedrock of income portfolios heading into the second half of 2026. Three of them stand out for July: a beaten-down quick-service leader, a biopharma machine firing on all cylinders, and a home improvement giant priced for a housing recovery that hasn’t fully arrived. Each pick offers a verified payout, a forward-looking thesis, and a clear risk to weigh.
McDonald’s (NYSE: MCD) McDonald’s (NYSE:MCD) is the classic “buy the weakness” setup right now. Shares traded around $275 on Monday, July 6, down more than 9% year to date and more than 6% over the past year. That underperformance has pushed the yield to 2.71% on an annualized payout of $7.26 per share.